Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug repurposing

BioData Mining20158:9

https://doi.org/10.1186/s13040-015-0042-8

Received: 5 August 2014

Accepted: 12 February 2015

Published: 25 February 2015

Abstract

Background

Pharmacogenomics (PGx) as an emerging field, is poised to change the way we practice medicine and deliver health care by customizing drug therapies on the basis of each patient’s genetic makeup. A large volume of PGx data including information among drugs, genes, and single nucleotide polymorphisms (SNPs) has been accumulated. Normalized and integrated PGx information could facilitate revelation of hidden relationships among drug treatments, genomic variations, and phenotype traits to better support drug discovery and next generation of treatment.

Methods

In this study, we generated a normalized and scientific evidence supported cancer based PGx network (CPN) by integrating cancer related PGx information from multiple well-known PGx resources including the Pharmacogenomics Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the Catalog of Published Genome-Wide Association Studies (GWAS). We successfully demonstrated the capability of the CPN for drug repurposing by conducting two case studies.

Conclusions

The CPN established in this study offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing.

Keywords

Pharmacogenomics Cancer Network Drug repurposing

Background

In 2003, the US Food and Drug Administration (FDA) recognized the importance of PGx data for the evaluation of drug safety and efficacy by starting a voluntary data exchange program, which requests that pharmaceutical companies submit genomic data along with their new drug packages. So far, the FDA has documented PGx information for more than 100 drugs associated with more than 50 genes [1]. Of these drugs, 42 FDA cancer drugs include PGx information in their package inserts. Clearly, cancer therapy is one of the most intensively studied topics in PGx [2-4], and relevant PGx data are accumulating quickly. Thus, it is critical to determine how to use and integrate cancer based PGx information effectively, thereby revealing hidden relationships among drug treatments, genomic variations, and phenotype traits and better supporting drug discovery and next generation of treatment. To our knowledge, no integration efforts have been directed specifically toward cancer based PGx. Suggested Ontology for Pharmacogenomics (SO-Pharm) [5] and Pharmacogenomics Ontology (PO) [6] are two existing ontologies for general PGx integration. They provided a first step toward integrating and representing PGx (and related) knowledge in the web ontology language (OWL), a web standard [7]. SO-Pharm contains so many classes and relations to represent generic PGx information that it is computationally expensive “and leads to significantly higher complexity for knowledge composition” [5]. It therefore presents challenges to users “in asserting knowledge or making routine queries” [5]. PO is a case-driven PGx data integration platform that aims to question-answering. Our study aims to integrate PGx information by focusing on oncology domain from diverse PGx resources. In addition, we will not only integrate existing PGx information, but also add inferred associations, which will support the novel indication detection for used drugs.

Idiosyncratic information without semantic interoperability and standard-based annotation, however, adds no value to the scientific commons. These idiosyncratic data must be annotated using standard terms and elements that correspond to the way scientists might search, integrate, inference, or expand upon the data. In the oncology community, the FDA and National Cancer Institute (NCI) attempt to document approved cancer drug information in a meaningful way. For instance, cancer drugs can be browsed by approved date with detailed description from the FDA [8]; they also can be queried/browsed by specific cancer type from the NCI [9], in which cancer drugs have been mapped to the NCI Thesaurus [2]. Nevertheless, to our knowledge, there is no data normalization effort made for cancer based PGx information. Lack of such effort hinders data sharing and further data integration. The CPN constructed in this study has been highlighted with normalization tags by leveraging the controlled terminologies and vocabularies.

In this study, we integrated multiple well known PGx resources including the PharmGKB [1], the FDA Pharmacogenomic Biomarkers in Drug Labeling [10] and the Catalog of Published Genome-Wide Association Studies [11], and represented terms by using relevant standards to construct a cancer based PGx network, named CPN (Cancer based PGx Network). This work was intended to demonstrate the feasibility of constructing the CPN to support possible drug repurposing candidate identification. To illustrate the capability of the CPN for drug repurposing, two case studies have been performed successfully.

Materials

NCI cancer list

National Cancer Institute (NCI) has maintained the alphabet links for information on a particular type of cancer. In this study, we have manually collected 160 distinct cancer types through de-duplication including bladder cancer, breast cancer, leukemia, and so on from NCI by Nov 14, 2013 [12].

Pharmacogenomics knowledge base (PharmGKB)

PharmGKB contains genomic, phenotype and clinical information collected from PGx studies. It provides information regarding variant annotations, drug-centered pathway, pharmacogenomic summaries, clinical annotations, PGx-based drug-dosing guidelines, and drug labels with PGx information [1]. In this study, we used PGx information extracted from a relationship file received from the PharmGKB by May 8, 2013, which provides associations between two PGx concepts, including drug, gene, disease, SNP and haplotype. Some examples are shown in Table 1. All fields listed in Table 1 were extracted and applied in this study.
Table 1

Examples of PGx associations extracted from the PharmGKB

Entity1_id

Entity1_ name

Entity1_ type

Entity2_id

Entity2_ name

Entity2_ type

PMIDs

PA443512

Urinary bladder neoplasms

Disease

rs762551

rs762551

Variant location

18798002

rs762551

rs762551

Variant location

PA443434

Arthritis, Rheumatoid

Disease

18496682

PA443434

Arthritis, Rheumatoid

Disease

PA27093

CYP1A2

Gene

18496682;19581389

PA27093

CYP1A2

Gene

PA450688

olanzapine

Drug

19636338;21519338

The detailed information about individual disease, drug and gene terms were extracted from the corresponding Disease, Drug and Gene files downloaded from the PharmGKB by November 15, 2013 [13].

FDA Pharmacogenomic biomarkers in drug labeling

The US Food and Drug Administration (FDA) provides a table of biomarkers for some FDA-approved drugs. The table contains “Therapeutic areas” field indicating the treatment intention of the drugs, such as “Oncology”, “Psychiatry”, etc., as well as the “HUGO Symbol” field representing associated genes. In this study we extracted these two fields that are “Oncology” related. The table was downloaded by Dec 3, 2013 [8].

Catalog of published genome-wide association studies

NIH provides a Catalog of Published Genome-Wide Association Studies (GWAS), which has identified single nucleotide polymorphisms (SNPs) and reported genes for major disease traits. We extracted cancers and related genes and SNPs from the “Disease/Trait”, the “Reported Gene(s)” and “SNPs” fields respectively. The Catalog was downloaded by Dec 3, 2013 [11].

National Center for Biomedical Ontology (NCBO)

The NCBO provides an ontology-based web service that can annotate public datasets with biomedical ontology concepts [14]. The reasons to select the NCBO bioportal for the normalization task in this study are 1) our previous work [15] has shown the capability of NCBO to support PGx data normalization, 2) its convenience of online access and its large scale of more than 400 ontologies [16] beyond other tools such as Metamap. We used the NCBO Bioportal REST service [17] to access biomedical ontologies. In this study, we utilized this service to normalize disease and drug terms with Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT) [18] and RxNorm [19].

SemMedDB

SemMedDB is a repository of semantic predications (subject-predicate-object triples) extracted from the entire set of PubMed citations with SemRep. The subject and object pair corresponds to UMLS Metathesaurus concepts, and the predicate to a relation type in an extended version of the semantic network. SemMedDB contains eight tables and is updated at regular intervals. We downloaded the latest PREDICATION_AGGREGATE table with ending date of MAR 31 2014 [20]. In this study, we identified scientific evidence, PubMed IDs from SemMedDB for PGx associations present in the CPN.

Methods

In this study, we designed an approach including four steps to generate the CPN: 1) cancer based PGx association identification, 2) cancer based PGx concept normalization, 3) scientific evidence identification, and 4) the CPN generation. In the first step, we identified cancer based PGx associations from the PharmGKB, the GWAS Catalog and the FDA Biomarker table. Then we mapped cancer based PGx concepts to standard vocabularies, for instance, drugs to RxNorm, diseases to SNOMED-CT, genes to HUGO gene symbol and so on. Once the PGx associations were normalized and scientific evidences were identified from SemMedDB, we built the CPN. Figure 1 presents the architecture developed for the CPN construction. More details about each step and case studies will be described in the following sections.
Figure 1

The architecture of the approach being used for the CPN construction.

Cancer based PGx association identification

To extract cancer based PGx associations, we first manually collected 160 distinct NCI cancer terms called as seeds from the NCI Cancer List. Then we performed an iterative search to identify PGx associations related to these seeds from PharmGKB. This search was not terminated until fourth-degree concepts that are four nodes away from the seeds have been extracted. More specifically, starting from those seeds, we searched for first-degree concepts that are directly connected to the seeds, then we retrieved second-degree concepts that are neighbors of the first degree concepts, followed by locating third-degree concepts that are neighbors of the second-degree concepts, then the fourth–degree concepts. We iteratively extracted associations related to these seeds from fields listed in Table 1. For instance, beginning with the seed “Urinary Bladder Neoplasms”, we can iteratively find associations, including “rs762551” - “Urinary Bladder Neoplasms”, “Arthritis, Rheumatoid” - “rs762551”, “CYP1A2” - “Arthritis, Rheumatoid”, and “Olanzapine” - “CYP1A2”, which are shown in Table 1. These pairs are as building blocks being used for constructing the CPN. Besides drug, disease and gene, we also extracted haplotype and SNP information that exist in the PharmGKB relationship file. To reflect an assumption that concepts with shorter distance to the seeds might have stronger associations with these seeds, we assigned different weight scores to PGx concepts based on their degrees. The first-degree concept was conferred with a higher weight score of “4”, then the second degree with “3”, the third degree with “2” and the fourth degree with “1”.

Additional PGx information available from the GWAS Catalog and the FDA biomarker table has also been extracted. We manually identified the seeds in the GWAS Catalog based on the NCI cancer terms. We then extracted the PGx associations related to the seeds from fields of “Disease/Trait”, “Reported Gene(s)” and “SNPs” in the GWAS Catalog. It is worthy to note that we did not perform an iterative search to find indirect associations from GWAS Catalog, as we were only interested in the associations extracted from this Catalog co-occurring in the PharmGKB. In parallel, we extracted PGx pairs between “Oncology” drugs and associated genes from the FDA biomarker table.

Cancer based PGx association normalization

We normalized disease terms by SNOMED-CT [18], drugs by RxNorm [19], genes by the Human Genome Organization (HUGO) [21] gene symbols, SNP by the National Center for Biotechnology Information [22] reference SNP ID number (rsID). Genes, SNPs, haplotypes derived from the three resources have already been represented in standard forms. Therefore, no additional normalization process has been performed accordingly. In this study, we primarily focused on the normalization for drug and disease terms.

A. Disease term normalization

PharmGKB provides manual annotations for disease terms with normalized vocabularies, including SNOMED-CT [18], Medical Subject Headings (MeSH) [23], Unified Medical Language System (UMLS) [24], etc., which are available in the downloadable Disease file. However, the mapping to SNOMED-CT is incomplete. There is no SNOMED-CT code available for cancer terms in GWAS catalog. Thus, we normalized disease terms that are without SNOMED-CT codes by employing the NCBO Bioportal REST service [17] programmatically. A Java program has been written to automatically invoke this REST service and parse the XML file as output to retrieve SNOMED-CT codes. Note that we specified “isexactmatch = 1” as one of the input parameters when executing the NCBO REST service. That is to say, the mapped SNOMED-CT terms are exactly matched to the input disease names, thus, no additional evaluation is needed to validate the mapping performance afterwards. We manually checked and mapped the unmapped disease terms to SNOMED-CT with their synonyms.

B. Drug term normalization

The same mapping strategy has been applied to drug terms, 1) we reused the normalized terms from the PharmGKB; 2) the NCBO Bioportal REST service was invoked to retrieve RxNorm Concept Unique Identifiers (RxCUIs) for those PharmGKB drugs and the drugs from the FDA biomarker table (no drug information in the GWAS catalog) that are without RxCUIs; 3) manual annotation was performed for unmapped drugs.

Two authors (LW, QZ) had reviewed and evaluated the mappings, and finalized the mapping lists for further CPN construction.

Scientific evidence identification

To insert scientific evidence, namely, published studies to support PGx associations presented in the CPN, we searched for SemMedDB accordingly. Besides PubMed references existing in the PharmGKB, we searched for PGx associations from the GWAS catalog and the FDA biomarker table against SemMedDB.

Cancer based PGx network construction

Once the cancer based PGx associations were identified, we linked concepts occurring across three resources to construct the CPN. In the CPN, the nodes correspond to individual cancer based PGx concepts including drug, gene, disease, SNP and haplotype. The edges correspond to PGx associations. Table 2 shows the types of PGx associations contained in the CPN.
Table 2

Types of association available in the CPN

Pairs Resources

Drug-gene

Drug-haplotype

Drug-disease

Drug-SNP

Drug-drug

Disease-SNP

Disease-hyplotype

Gene-disease

Gene-gene

Gene-SNP

PharmGKB

 

 

GWAS catalog

     

 

 

FDA biomarkers

 

       

Results

Cancer based PGx association identification

A. PharmGKB

Total 38 distinct seeds have been identified from the PharmGKB. Accordingly, we have extracted 2,964 concepts that are associated with these seeds, corresponding to 13,221 PGx pairs. Among these pairs, there are 402 drugs, 205 diseases, 825 genes, 1333 SNPs and 199 haplotypes.

Table 3 shows results of PGx associations extracted from the PharmGKB. For example, there are 38 seeds (cancer terms) associated with 393 Disease-Gene pairs, 37 Disease-Haplotype pairs and 530 Disease-SNP pairs. The numbers shown in Table 3 are unique.
Table 3

Results of PGx association extraction from the PharmGKB

Degree of concepts

Number of concepts

No. of pairs

Disease-gene

Disease-haplotype

Disease-SNP

Drug-gene

Drug-haplotype

Drug-SNPs

Drug-drug

Gene-gene

Seeds

38

393

37

530

0

0

0

0

0

1

605

1018

50

1155

1827

77

1607

0

195

2

735

1700

278

2483

2972

974

3716

1

944

3

2646

1705

277

2492

2965

974

3710

1

982

4

1196

0

0

0

0

0

0

0

0

Total

2964

1723

277

2500

3012

974

3718

1

1016

B. FDA biomarkers and GWAS catalog

We manually identified 42 cancer drugs from the FDA biomarker table. As some of drugs are associated with multiple genes, total 55 drug and gene pairs corresponding to 44 genes were extracted.

We extracted 31 cancer terms from the GWAS catalog, of which there are 2455 PGx pairs corresponding to 720 genes and 598 SNPs.

Cancer based PGx association normalization

Among 402 drugs extracted from the PharmGKB in this study, RxCUIs are available for 323 drugs. For the rest of 79 drugs without RxCUIs, 53 were mapped to RxNorm by invoking the NCBO REST service programmatically. For 205 PharmGKB disease terms being used in this study, SNOMED-CT codes are available for 186 disease terms. Another 10 diseases were mapped to SNOMED-CT by invoking the NCBO REST service programmatically. Of 42 drugs from the FDA biomarker table, 41 were mapped to RxNorm by using NCBO REST service. Of 31 cancer terms identified from the GWAS Catalog, 29 were mapped to SNOMED-CT by the NCBO REST service. Furthermore, we manually mapped 5 drugs and 8 diseases to the standards accordingly.

In summary, 394 out of 416 (94.7%) unique drug concepts have been mapped to RxNorm, and 215 out of 218 (98.6%) unique disease concepts been mapped to SNOMED-CT. Reasons for the failed mapping will be discussed in the discussion section.

Scientific evidence identification

Besides PubMed references existing in the PharmGKB, 19 PGx pairs corresponding to 16 drugs and 13 genes in the FDA biomarker table were retrieved to be with PubMed IDs and 6 predicates including “COEXISTS_WITH”, “compared_with”, “higher_than”, “INHIBITS”, “INTERACTS_WITH” and “USES” from the SemMedDB. Meanwhile, total 253 PGx pairs (24 diseases and 89 genes) from the GWAS Catalog were retrieved to be with PubMed IDs and 8 predicates including “AFFECTS”, “ASSOCIATED_WITH”, “AUGMENTS”, “CAUSES”, “NEG_ASSOCIATED_WITH”, “NEG_PART_OF”, “PART_OF” and “PREDISPOSES” from the SemMedDB.

Cancer based PGx network (CPN)

The CPN contains 4,342 distinct nodes and 15,600 pairs in total. We explored Cytoscape [25] to visualize the CPN. A sub-network extracted from the CPN specifically for “urinary bladder cancer” is shown at the left lower corner of Figure 1.

Case studies

The CPN provides comprehensive PGx information to support advanced cancer relevant research. Specifically, we can identify possible drug repurposing candidates from the CPN by utilizing network analysis approaches. The below two case studies illustrate the capability of the CPN for drug repurposing. It is worthy to note that we manually identified relevant literatures to further evaluate the findings produced in these two case studies and the feasibility of this present study for drug repurposing. However, the ultimate goal of this study is to identify novel drug repurposing candidates that are without supportive scientific evidences, and they will attract interests of chemists and/or biologists for further experimental evaluation.

A. Case study 1

Paclitaxel is used to treat Kaposi’s sarcoma, as well as the lung, ovarian, and breast cancer, as documented in the “Indications & Usage” section of the structured product label [26]. In this case study, we were interested in revealing the new indications of Paclitaxel from the CPN. We searched the CPN for Paclitaxel with RxCUI = “56946” and identified relevant disease concepts that are at most 3 nodes away from the Paclitaxel. More specifically, we searched for direct and indirect disease associations that are relevant to Paclitaxel and those disease nodes are at most 3 nodes away from Paclitaxel. In total, there are 70 concepts directly associated with Paclitaxel, 399 concepts including 110 disease concepts that are two nodes away from Paclitaxel, and 1689 concepts including 110 disease concepts that are three nodes away from Paclitaxel. To further evaluate and determine the possible novel indications and the appropriateness of our approach, we manually sought scientific evidences from PubMed literatures to support new indications inferred from the CPN. As a result, 20% newly identified indications including Alzheimer Disease, Asthenia, Leukemia, etc. for Paclitaxel are supported by published studies. To detail our approach, Alzheimer Disease as one novel indication identified for Paclitaxel from the CPN is shown as below.

“MTHFR” and rs1801133” are the two direct nodes connected to Paclitaxel, subsequently “Alzheimer Disease” with SNOMED-CT code, “26929004” has been identified via the above two nodes, as shown in Figure 2. rs1801133 is encoding a variant in the MTHFR gene, which encodes an enzyme involved in folate metabolism [27]. Then associations of Paclitaxel-MTHFR-“Alzheimer Disease”, can be further validated by literatures as follows, 1) Paclitaxel enhanced the inhibition of MTHFR by antisense or small molecules, which decreases tumor growth [28]; 2) The severity and biochemical risk factors of Alzheimer’s disease may be influenced by the MTHFR 677 T allele in an Egyptian population [29] and the association between MTHFR A1298C polymorphisms as a possible risk factor and Alzheimer’s disease was verified [30].
Figure 2

A sub-network of Paclitaxel taken from the CPN. Blue solid lines indicate the direct association existed in the CPN, while the red dotted line indicates the indirect inference applied in this case study.

By analyzing the CPN, Paclitaxel is related to “Alzheimer Disease” via gene MTHFR and SNP “rs1801133”. In addition, evidences are mounting in the literature that Alzheimer disease may be a new indication of the cancer drug Paclitaxel, for example Paclitaxel may rescue neurons from undergoing hallmark tau-induced Alzheimer disease cell pathologies [31] and Paclitaxel has the potential to treat Alzheimer disease [32]. That is to say,Paclitaxel may be a potential drug repurposing candidate for the treatment of Alzheimer Disease.

B. Case study 2

Capecitabine is originally indicated for the treatment of breast cancer and colorectal cancer as stated in the drug label [33]. In this case study, we aimed to seek alternative indications for Capecitabine. We searched for Capecitabine with RxCUI “194000” from the CPN to identify novel indications. In total, there are 120 disease nodes that are at most 3 nodes away from Capecitabine. Of these 120 diseases, 12 possible novel indications including Hyperbilirubinemia, Mesothelioma, Bladder Neoplasm, etc. associated with Capecitabine are supported by published studies. The following example illustrates the identification process of the new indication, bladder neoplasm for Capecitabine.

From the CPN 50 directly relevant nodes have been retrieved for Capecitabine including the gene CYP1A1, from which “Urinary Bladder Neoplasms” have been identified subsequently. A sub-network of Capecitabine visualized by Cytoscape in the CPN is shown at the right lower corner in Figure 1, where the edges in red indicate all associations with Capecitabine, and the green edges indicate DPYD and C18orf56 are linking to Capecitabine respectively. The zoomed out network is shown in Figure 3. The association between “Urinary Bladder Neoplasms” and “Capecitabine” could be inferred through multiple paths as shown in Figure 3. Among all paths between these two, the shortest path is Capecitabine-CYP1A1-Urinary Bladder Neoplasms, of which the association could be proved by literatures: (1) “CYP1A1 rs1048943 A > G (Ile462Val) polymorphism is a potential prognostic marker for survival outcome after docetaxel plus capecitabine chemotherapy” [34]; (2) active CYP1A1 and CYP1B1 overexpression is revealed in bladder cancer [35]; (3) the combination of Capecitabine and radiation therapy offers a promising treatment option for bladder cancer patients who are not candidates for surgery or cisplatin-based chemotherapy [36]; (4) a patient with metastatic bladder cancer responded well to second-line capecitabine with a clinically meaningful progression-free survival [37]. Through this validation chain, the inference that the breast and colorectal cancer drug, “Capecitabine” might be used for urinary bladder cancer could be made. Evidently urinary bladder cancer may be a novel indication of Capecitabine via the network-based analysis of the CPN.
Figure 3

A sub-network of Capecitabine taken from the CPN. Blue solid lines indicate the direct association existed in the CPN, while the red dotted line indicates the indirect inference applied in this case study.

Discussion

Benefits gained from the CPN

A. Supporting further data integration

Data integration is essential in the big data era. It is important to aggregate different pieces of data from different areas to solve fundamental scientific questions. Particularly, in this study we have integrated data from various PGx data resources and built a cancer based PGx data repository. The concepts (nodes) included in the CPN were normalized with multiple standard biomedical terminologies and domain standards. Once the normalization task is accomplished, more relevant data can be deposited and integrated into the CPN, such as Electronic Medical Records (EHRs), DrugBank [38] and KEGG [39]. Besides a majority portion (99.4%) of the concepts has been normalized, about 0.6% of concepts was failed to be normalized. The reason of failure is in two folds. First, chemical IUPAC names were used as drug names in the PharmGKB, which were not included in RxNorm, e.g., “1-methyloxy-4-sulfone-benzene”. Second, drug class names were being used, such as “Analgesics and Anesthetics” and “Antiinflammatory and Antirheumatic Products”. In terms of diseases, the names were either presented too broadly, such as, “Substance-Related Disorders” or too narrowly, such as “Therapy Related Acute Myeloid Leukemia”, so that they cannot be mapped to SNOMED-CT.

B. Supporting oncology based drug discovery

PGx data including the detailed information for drugs, diseases, genes, SNPs, etc., has been regarded as a basis for individualized medicine. While generic PGx data could be obtained publicly, drug, disease, gene, SNP and haplotype resources have not, as yet, been well-integrated to support the oncology based drug discovery. With various association types including Disease-Gene, Drug-Gene, etc. as shown in Table 2, the CPN can serve as a highly relevant cancer knowledge base and a valuable platform for oncology based research on drug repurposing. Thus, it would result in the shortening of the entire process for drug development, as our case studies have successfully proved such capability of the CPN. Additionally two advantages inherent in the CPN will strengthen its application in drug repurposing, including: 1) the CPN contains both direct and indirect cancer based PGx associations, thus, more drug candidates can be identified via automated inference; 2) a majority of concepts contained in the CPN are normalized with standard vocabularies, which enables further integration with other relevant resources to support more novel indication identifications.

Limitation and future study

A. Path ranking

The current version of the CPN includes cancer based PGx information extracted from three major PGx resources. Although only 38 cancer terms have been found in the PharmGKB, 42 cancer drugs identified from the FDA biomarker table, and 31 cancer terms found from the GWAS catalog, the total number of nodes and edges of the CPN is 19,942, as we included all associations up to four nodes away from the cancer seeds. In this study, we focused on the CPN construction and the demonstration of the capability of the CPN. Path ranking to output a ranked list of paths that are associated with specific concepts from the CPN was out of scope of this study. However, when we conducted case studies, in order to filter out the most significant paths based on the queries, some initial ranking rules have been applied. For example, weight scores according to the degrees of concepts, path length, and VIP pairs from the PharmGKB have been applied for path ranking. In the future study, we will incorporate these rules with other ranking methods, such as PageRank [40], and genetic association p-values derived from GWAS [11], to output the most correlated paths for a particular query.

B. Disambiguating drug-disease association

Detailed information on specifying drug and disease association is critical for drug repurposing, as we have to determine whether this drug is used to treat this disease or this drug may cause such a disease as an adverse drug event. Consequently, the novel indication may be identified for this drug for further evaluation. In this study, all drug and disease associations were directly extracted from the original resources, no additional step has been applied to disambiguate such associations. In our previous study, we have employed NDF-RT and SPLs to annotate drug and disease relationships in the PharmGKB [41]. We will apply the annotation results [41] along with the existing annotations from NDF-RT, ADEpedia [42], LinkedSPLs [43] into the future study, inserting a particular tag for differentiating indications and adverse drug events.

C. Scientific evidence identification

The established CPN is supported by published studies, PubMed references extracted from SemMedDB. However, not all CPN associations have been assigned with pubmed IDs. 36 PGx pairs from the FDA biomarker table and 2202 PGx pairs from the GWAS Catalog were not mapped. SemRep, a rule-based semantic interpreter extracting predicates in Pubmed references being applied by SemMedDB, has shown its precision for gene-disease relations as 76% [44]; the precision and recall for pharmacogenomics as 73% and 55% [45] respectively. Thus we doubt that all association presented in this study have been extracted and included in SemMedDB. On the other hand, we performed direct mapping with FDA biomarker table and the GWAS Catalog that may cause missing mappings. In the future, we would use machine learning and natural language processing (NLP) to identify more associations on the basis of existing PubMed references.

D. Data integration

In this preliminary study, we extracted and integrated three well-known PGx resources to build the CPN. To make the CPN more informative, we will extract further cancer based PGx information from other public PGx resources, such as DrugBank, KEGG, etc., them and integrate into the CPN. Meanwhile, we will identify PGx associations from pathways, and apply NLP [46] tools and algorithms to automatically extract such associations from literatures periodically. The ultimate goal will be leveraging semantic web technologies (SWT) [47] to present such comprehensive cancer based PGx information in RDF [48] or OWL [49], which can support automated inference for drug repurposing.

Conclusions

In this study we have integrated three existing PGx resources into the CPN, which is supported by published studies, PubMed references extracted from SemMedDB. The established CPN offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing, the potential of which has been successfully demonstrated by case studies.

Abbreviations

PGx: 

Pharmacogenomics

SNPs: 

Single nucleotide polymorphisms

CPN: 

Cancer based PGx network

PharmGKB: 

Pharmacogenomics knowledge base

GWAS: 

Genome-wide association studies

OWL: 

Web ontology language

NCI: 

National Cancer Institute

SNOMED-CT: 

Systematized nomenclature of medicine-clinical terms

NCBO: 

National Center for Biomedical Ontology

MeSH: 

Medical subject headings

UMLS: 

Unified medical language system

rsID: 

Reference SNP ID number

Declarations

Acknowledgements

This work was supported by the Pharmacogenomic Research Network (NIH/NIGMS-U19 GM61388).

Authors’ Affiliations

(1)
Department of Medical Informatics, School of Public Health, Jilin University
(2)
Department of Health Science Research, Mayo Clinic
(3)
Division of General Internal Medicine, Johns Hopkins University
(4)
Department of Information Systems, University of Maryland Baltimore County

References

  1. Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB, et al. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res. 2002;30(1):163–5.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Fu B, Brennan R, O’Sullivan D. A configurable translation-based cross-lingual ontology mapping system to adjust mapping outcomes. Web Semant Sci Serv Agents World Wide Web. 2012;15:15–36.View ArticleGoogle Scholar
  3. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–4.PubMedPubMed CentralView ArticleGoogle Scholar
  4. Kreso A, O’Brien CA, van Galen P, Gan F, Notta OI, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013;339(6119):543–8.PubMedView ArticleGoogle Scholar
  5. Coulet A, Smaïl-Tabbone M, Napoli A, Devignes MD. Suggested ontology for pharmacogenomics (SO-Pharm): modular construction and preliminary testing. On the Move to Meaningful Internet Systems 2006: OTM 2006 Workshops. Springer Berlin Heidelberg, 2006: 648-657.Google Scholar
  6. Dumontier M, Villanueva-Rosales N. Towards pharmacogenomics knowledge discovery with the semantic web. Brief Bioinform. 2009;10(2):153–63.PubMedView ArticleGoogle Scholar
  7. Antoniou G, Van Harmelen F. Web ontology language: Owl. Handbook on ontologies. Springer Berlin Heidelberg, 2004: 67-92.Google Scholar
  8. FDA table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm. Accessed Jan 14, 2014.
  9. Kumar SK, Harding JA. Ontology mapping using description logic and bridging axioms. Comput Ind. 2013;64(1):19–28.View ArticleGoogle Scholar
  10. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy. 2008;28(8):992–8.PubMedView ArticleGoogle Scholar
  11. Hindorff LA MJEBI, Morales J (European Bioinformatics Institute), Junkins HA, Hall PN, Klemm AK, and Manolio TA. A catalog of published genome-wide association studies. www.genome.gov/gwastudies. Accessed Jan 14, 2014.
  12. National Cancer Institute. http://www.cancer.gov/cancertopics/types/alphalist. Accessed Jan 14, 2014.
  13. The pharmcogenomics knowledgebase. http://www.pharmgkb.org/. Accessed Jan 14, 2014.
  14. Whetzel PL, Noy NF, Shah NH, Alexander PR, Nyulas C, Tudorache T, et al. BioPortal: enhanced functionality via new web services from the National Center for Biomedical Ontology to access and use ontologies in software applications. Nucleic Acids Res. 2011;39 suppl 2:W541–5.PubMedPubMed CentralView ArticleGoogle Scholar
  15. Zhu Q, Freimuth RR, Lian Z, Bauer S, Pathak J, Tao C, et al. Harmonization and semantic annotation of data dictionaries from the pharmacogenomics research network: a case study. J Biomed Inform. 2013;46(2):286–93.PubMedView ArticleGoogle Scholar
  16. Whetzel PL, NCBO Team. NCBO Technology: Powering semantically aware applications. J Biomedical Semantics. 2013;4(S-1):S8.View ArticleGoogle Scholar
  17. National center for biomedical ontology rest service. http://data.bioontology.org/documentation. Accessed Jan. 14, 2014.
  18. Bos L. SNOMED-CT: the advanced terminology and coding system for eHealth. Med Care Compunetics 3. 2006;121:279.Google Scholar
  19. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18(4):441–8.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Kilicoglu H, Fiszman M, Rodriguez A, Shin D, Ripple A, Rindflesch TC. Semantic MEDLINE: a web application for managing the results of PubMed Searches. Proceedings of the third international symposium for semantic mining in biomedicine. 2008: 69-76.Google Scholar
  21. Gardiner K. Human genome organization. Curr Opin Genet Dev. 1995;5(3):315–22.PubMedView ArticleGoogle Scholar
  22. Sayers EW, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2011;39 suppl 1:D38–51.PubMedView ArticleGoogle Scholar
  23. Coletti MH, Bleich HL. Medical subject headings used to search the biomedical literature. J Am Med Inform Assoc. 2001;8(4):317–23.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Bodenreider O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2004;32 suppl 1:D267–70.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, et al. A travel guide to Cytoscape plugins. Nat Methods. 2012;9(11):1069–76.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Drug label of paclitaxel in dailymed. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid–9ffd3e34–537f–4f65-b00e–57c25bab3b01#nlm34067–9. Accessed Feb 20, 2014.
  27. Yu L, Chen J. Association of MHTFR Ala222Val (rs1801133) polymorphism and breast cancer susceptibility: an update meta-analysis based on 51 research studies. Diagn Pathol. 2012;7(1):171.PubMedPubMed CentralView ArticleGoogle Scholar
  28. Stankova J, Shang J, Rozen R. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo. Clin Cancer Res. 2005;11(5):2047–52.PubMedView ArticleGoogle Scholar
  29. Elhawary NA, Hewedi D, Arab A, Teama S, Shaibah H, Tayeb MT, et al. The MTHFR 677 T allele may influence the severity and biochemical risk factors of Alzheimer’s disease in an Egyptian population. Dis Markers. 2013;35(5):439–46.PubMedPubMed CentralView ArticleGoogle Scholar
  30. Mansouri L, Fekih-Mrissa N, Klai S, Mansour M, Gritli N, Mrissa R. Association of methylenetetrahydrofolate reductase polymorphisms with susceptibility to Alzheimer’s disease. Clin Neurol Neurosurg. 2013;115(9):1693–6.PubMedView ArticleGoogle Scholar
  31. Shemesh OA, Spira ME. Rescue of neurons from undergoing hallmark tau-induced Alzheimer’s disease cell pathologies by the antimitotic drug paclitaxel. Neurobiol Dis. 2011;43(1):163–75.PubMedView ArticleGoogle Scholar
  32. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A. 2005;102(1):227–31.PubMedView ArticleGoogle Scholar
  33. Drug label of capecitabine in dailymed. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a1de8bba–3b1d–4c9d-ab8a–32d2c05e67c8. Accessed Jan 14, 2014.
  34. Dong N, Yu J, Wang C, Zheng X, Wang Z, Di L, et al. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. J Cancer Res Clin Oncol. 2012;138(7):1197–203.PubMedView ArticleGoogle Scholar
  35. Androutsopoulos VP, Spyrou I, Ploumidis A, Papalampros AE, Kyriakakis M, Delakas D, et al. Expression Profile of CYP1A1 and cyp1b1 enzymes in colon and bladder tumors. PLoS One. 2013;8(12):e82487.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Patel B, Forman J, Fontana J, Frazier A, Pontes E, Vaishampayan U. A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol Phys. 2005;62(5):1332–8.PubMedView ArticleGoogle Scholar
  37. Michels J, Barbour S, Cavers D, Chi KN. Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature. Can Urol Assoc J. 2010;4(2):E55–57.PubMedPubMed CentralGoogle Scholar
  38. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34 suppl 1:D668–72.PubMedView ArticleGoogle Scholar
  39. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.PubMedPubMed CentralView ArticleGoogle Scholar
  40. Page L, Brin S, Motwani R, Winograd T. The PageRank citation ranking: bringing order to the web. 1999.Google Scholar
  41. Zhu Q, Freimuth RR, Pathak J, Durski MJ, Chute CG. Disambiguation of PharmGKB drug–disease relations with NDF-RT and SPL. J Biomed Inform. 2013;46(4):690–6.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Jiang G, Solbrig HR, Chute CG. ADEpedia: a scalable and standardized knowledge base of Adverse Drug Events using semantic web technology. AMIA annual symposium proceedings. Am Med Inform Assoc. 2011;2011:607–16.Google Scholar
  43. Hassanzadeh O, Zhu Q, Freimuth R, Boyce R. Extending the “Web of Drug Identity” with Knowledge Extracted from United States Product Labels. AMIA Summits Transl Sci Proc. 2013;2013:64–8.PubMedPubMed CentralGoogle Scholar
  44. Rindflesch TC, Libbus B, Hristovski D, Aronson AR, Kilicoglu H. Semantic relations asserting the etiology of genetic diseases. AMIA Annual Symposium Proceedings. Am Med Inform Assoc. 2003;2003:554–8.Google Scholar
  45. Ahlers CB, Fiszman M, Demner-Fushman D, Lang FM, Rindflesch TC. Extracting semantic predications from Medline citations for pharmacogenomics. Pac Symp Biocomput. 2007;12:209–20.Google Scholar
  46. Chowdhury GG. Natural language processing. Annu Rev Info Sci Technol. 2003;37(1):51–89.View ArticleGoogle Scholar
  47. Berners-Lee T, Hendler J, Lassila O. The semantic web. Sci Am. 2001;284(5):28–37.View ArticleGoogle Scholar
  48. McBride B. The resource description framework (RDF) and its vocabulary description language RDFS. Handbook on ontologies. Springer Berlin Heidelberg, 2004: 51-65.Google Scholar
  49. McGuinness DL, Van Harmelen F. OWL web ontology language overview. W3C Recomm. 2004;10(10):2004. http://www.w3.org/TR/owl-features/.Google Scholar

Copyright

© Wang et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.